Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: 21(12), P. 1376 - 1409
Published: Nov. 8, 2024
АBSTRACT: With increasing incidence and geography, cancer is one of the leading causes death, reduced quality life disability worldwide. Principal progress in development new anticancer therapies, improving efficiency immunotherapeutic tools, personification conventional therapies needs to consider cancer-specific patient-specific programming innate immunity. Intratumoral TAMs their precursors, resident macrophages monocytes, are principal regulators tumor progression therapy resistance. Our review summarizes accumulated evidence for subpopulations number biomarkers, indicating predictive value clinical parameters carcinogenesis resistance, with a focus on solid cancers non-infectious etiology. We present state-of-the-art knowledge about tumor-supporting functions at all stages highlight recently identified by single-cell spatial analytical methods, that discriminate between tumor-promoting tumor-inhibiting TAMs, where both subtypes express combination prototype M1 M2 genes. focuses novel mechanisms involved crosstalk among epigenetic, signaling, transcriptional metabolic pathways TAMs. Particular attention has been given link cell metabolism epigenetic histone lactylation, which can be responsible unlimited protumoral Finally, we explain how interfere currently used therapeutics summarize most advanced data from trials, divide into four categories: inhibition TAM survival differentiation, monocyte/TAM recruitment tumors, functional reprogramming genetic enhancement macrophages.
Language: Английский
Citations
14
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: April 12, 2024
Surgery, chemotherapy, and endocrine therapy have improved the overall survival postoperative recurrence rates of Luminal A, B, HER2-positive breast cancers but treatment modalities for triple-negative cancer (TNBC) with poor prognosis remain limited. The effective application rapidly developing chimeric antigen receptor (CAR)-T cell in hematological tumors provides new ideas cancer. Choosing suitable specific targets is crucial applying CAR-T treatment. In this paper, we summarize therapy’s potential different subtypes based on existing research progress, especially TNBC. CAR-based immunotherapy has resulted advancements CAR-macrophages, CAR-NK cells, CAR-mesenchymal stem cells (MSCs) may be more safer treating solid tumors, such as However, tumor microenvironment (TME) side effects pose challenges to immunotherapy. cells-derived exosomes are advantageous therapy. Exosomes carrying CAR immense value provide a modality good effects. review, an overview development discuss progress CAR-expressing We elaborate TNBC prospects using CAR-MSCs
Language: Английский
Citations
13
Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)
Published: Aug. 5, 2024
Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.
Language: Английский
Citations
12
Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)
Published: March 15, 2025
Abstract In the last two decades, novel and promising cell-based therapies have populated treatment landscape for haematological tumors. However, commonly exploited T NK show limited applicability to solid This is mainly given by impaired tumor trafficking capability effector activity of these cells within a highly immunosuppressive microenvironment. Myeloid spontaneously home tumors can thus be reprogrammed and/or engineered directly attack or locally selectively deliver therapeutically relevant payloads that may improve efficacy immunotherapy against difficult-to-access context myeloid therapies, adoptive transfer monocytes has often been overshadowed infusion differentiated macrophages hematopoietic stem cell transplantation despite their therapeutic potential. Here, we summarize recent improvements benefits using tumors, current clinical applications challenges use as well some possible strategies overcome them.
Language: Английский
Citations
1
Biochemical Pharmacology, Journal Year: 2024, Volume and Issue: 226, P. 116349 - 116349
Published: June 7, 2024
Language: Английский
Citations
6
Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12
Published: Oct. 3, 2024
Chimeric Antigen Receptor (CAR) technology has revolutionized cellular immunotherapy, particularly with the success of CAR-T cells in treating hematologic malignancies. However, have limited efficacy against solid tumors. To address these limitations, CAR-macrophages (CAR-Ms) leverage innate properties macrophages specificity and potency CAR technology, offering a novel promising approach to cancer immunotherapy. Preclinical studies shown that CAR-Ms can effectively target destroy tumor cells, even within challenging microenvironments, by exhibiting direct cytotoxicity enhancing recruitment activation other immune cells. Additionally, favorable safety profile their persistence tumors position as potentially safer more durable therapeutic options compared This review explores recent advancements including engineering strategies optimize anti-tumor preclinical evidence supporting use. We also discuss challenges future directions developing therapies, emphasizing potential revolutionize By harnessing unique macrophages, offer groundbreaking overcoming current limitations cell paving way for effective sustainable treatments.
Language: Английский
Citations
6
Cancer Biology and Medicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 15
Published: Sept. 19, 2024
Neutrophils, which originate from the bone marrow and are characterized by a segmented nucleus brief lifespan, have crucial role in body’s defense against infections acute inflammation. Recent research has uncovered complex roles of neutrophils as regulators tumorigenesis, during exhibit dualistic nature that promotes or inhibits tumor progression. This adaptability is pivotal within microenvironment (TME). In this review, we provide comprehensive characterization neutrophil plasticity heterogeneity, aiming to illuminate current findings discuss potential therapeutic avenues. By delineating intricate interplay TME, review further underscores urgent need understand dual functions with particular emphasis on anti-tumor effects facilitate development effective strategies cancer.
Language: Английский
Citations
5
Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)
Published: Jan. 4, 2025
Summary Breast cancer will overtake all other cancers in terms of diagnoses 2024. counts highest among women incidence and death rates. Innovative treatment approaches are desperately needed because resistance brought on by current clinical drugs impedes therapeutic efficacy. The T cell-based immunotherapy known as chimeric antigen receptor (CAR) cell treatment, which uses the patient’s immune cells to fight cancer, has demonstrated remarkable efficacy treating hematologic malignancies; nevertheless, effects solid tumors, like breast have not lived up expectations. We discuss detail role tumor-associated antigens trials, barriers intended CAR-T therapy, potential ways increase Finally, our review aims stimulate readers’ curiosity summarizing most recent advancements therapy for cancer.
Language: Английский
Citations
0
Cell Reports Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 101931 - 101931
Published: Jan. 1, 2025
Chimeric antigen receptor (CAR) T cell therapy is a promising immunotherapy against cancer. Although there growing interest in other types, comparison of CAR immune effector cells challenging solid tumor contexts lacking. Here, we compare mouse and human NKG2D-CAR-expressing cells, natural killer (NK) macrophages glioblastoma, the most aggressive primary brain tumor. Invitro show that cancer killing dependent, whereas intrinsic cytotoxicity overrules dependence for NK reduce glioma co-culture assays. In orthotopic immunocompetent models, systemically administered demonstrate superior accumulation tumor, each type induces distinct changes microenvironment. An otherwise low therapeutic efficacy significantly enhanced by co-expression pro-inflammatory cytokines all underscoring necessity multifaceted engineering strategies to overcome immunosuppressive
Language: Английский
Citations
0
Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 262, P. 155518 - 155518
Published: Aug. 10, 2024
Language: Английский
Citations
3